Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.34 |
| ▸ | GLRA3 | O75311 | 2/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | GLRB | P48167 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL988568 | 0.92 | CCR1 (0.37) | HSD11B1NR1I2GLRA3SLC6A9F2 | |
| SCHEMBL990369 | 0.87 | SLC6A2 (0.42) | HSD11B1CNR1NR1I2SLC6A9F2 | |
| SCHEMBL991124 | 0.86 | CYP3A4 (0.35) | HSD11B1NR1I2SLC6A9SCN9ACYP3A4 | |
| SCHEMBL989705 | 0.83 | SLC6A9 (0.46) | HSD11B1NR1I2SLC6A9SCN9ACYP3A4 | |
| SCHEMBL988874 | 0.80 | HSD11B1 (0.36) | HSD11B1NR1I2SCN9ACYP3A4SLC6A4 | |
| SCHEMBL989592 | 0.78 | SLC6A9 (0.42) | HSD11B1SLC6A9F2CYP3A4SLC6A2 | |
| SCHEMBL989583 | 0.78 | CCR1 (0.41) | HSD11B1NR1I2SLC6A9F2CYP3A4 | |
| SCHEMBL8026429 | 0.77 | SLC6A9 (0.53) | CNR1GLRA3SLC6A9F2SCN9A | |
| SCHEMBL991099 | 0.76 | DRD2 (0.41) | CNR1SCN9A | |
| SCHEMBL988781 | 0.76 | SLC6A9 (0.41) | HSD11B1SLC6A9F2CYP3A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105502-A1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott BmbH & Co. KG (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-2271625-A2 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105502-A1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | GOLT1B, SLC10A1, SUGT1 | HSD11B1 1303/4885CNR1 740/4885NR1I2 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.